| Literature DB >> 35424256 |
Nguyen Minh Tam1,2, Pham Cam Nam3, Duong Tuan Quang4, Nguyen Thanh Tung5,6, Van V Vu7, Son Tung Ngo2,8.
Abstract
SARS-CoV-2 rapidly infects millions of people worldwide since December 2019. There is still no effective treatment for the virus, resulting in the death of more than one million patients. Inhibiting the activity of SARS-CoV-2 main protease (Mpro), 3C-like protease (3CLP), is able to block the viral replication and proliferation. In this context, our study has revealed that in silico screening for inhibitors of SARS-CoV-2 Mpro can be reliably done using the monomeric structure of the Mpro instead of the dimeric one. Docking and fast pulling of ligand (FPL) simulations for both monomeric and dimeric forms correlate well with the corresponding experimental binding affinity data of 24 compounds. The obtained results were also confirmed via binding pose and noncovalent contact analyses. Our study results show that it is possible to speed up computer-aided drug design for SARS-CoV-2 Mpro by focusing on the monomeric form instead of the larger dimeric one. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35424256 PMCID: PMC8694027 DOI: 10.1039/d0ra09858b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1Computational scheme for evaluation of the ligand-binding affinity to the monomeric and dimeric SARS-CoV-2 Mpro.
Computed values of docking energy in comparison with experiments
| No. | Name | Δ | Δ | Δ | ||||
|---|---|---|---|---|---|---|---|---|
| Short | Medium | Long | Short | Medium | Long | |||
| 1 | 7j | −7.2 | −7.4 | −7.2 | −7.6 | −7.4 | −7.3 | −8.69 |
| 2 | 11a | −7.5 | −7.6 | −7.6 | −7.2 | −7.1 | −7.1 | −9.96 |
| 3 | 11b | −8.0 | −8.1 | −8.0 | −7.3 | −7.4 | −7.4 | −10.13 |
| 4 | 11r | −6.7 | −6.4 | −6.3 | −7.9 | −8.1 | −8.3 | −9.23 |
| 5 | 13a | −7.6 | −7.6 | −7.6 | −8.0 | −7.8 | −7.8 | −7.70 |
| 6 | 13b | −7.6 | −7.8 | −7.8 | −7.6 | −7.1 | −7.8 | −8.45 |
| 7 | Calpain inhibitor I | −5.2 | −5.2 | −5.2 | −5.4 | −5.4 | −5.6 | −6.94 |
| 8 | Calpain inhibitor II | −5.3 | −5.5 | −5.5 | −5.5 | −5.7 | −5.6 | −8.23 |
| 9 | Calpain inhibitor XII | −6.2 | −6.3 | −6.3 | −7.3 | −7.3 | −7.2 | −8.69 |
| 10 | Calpeptin | −5.8 | −5.5 | −6.1 | −6.1 | −6.4 | −6.3 | −6.81 |
| 11 | Candesartan cilexetil | −7.5 | −7.4 | −7.9 | −7.9 | −8.4 | −8.4 | −7.60 |
| 12 | Carmofur | −5.2 | −5.5 | −5.6 | −5.7 | −5.8 | −6.1 | −7.86 |
| 13 | Chloroquine | −5.0 | −5.3 | −5.1 | −6.6 | −6.6 | −6.6 | −7.41 |
| 14 | Dipyridamole | −6.5 | −6.5 | −6.6 | −6.7 | −6.6 | −6.6 | −8.52 |
| 15 | Disulfiram | −3.9 | −3.8 | −3.9 | −4.3 | −4.1 | −4.1 | −6.89 |
| 16 | GC-373 | −7.0 | −7.0 | −7.1 | −6.5 | −6.8 | −7.0 | −8.76 |
| 17 | Hydroxychloroquine | −5.8 | −6.3 | −6.2 | −6.1 | −6.2 | −6.5 | −7.58 |
| 18 | MG-115 | −5.7 | −5.7 | −5.5 | −5.7 | −5.7 | −6.1 | −7.53 |
| 19 | MG-132 | −5.6 | −6.2 | −6.2 | −6.1 | −5.8 | −6.2 | −7.41 |
| 20 | Narlaprevir | −7.8 | −7.5 | −7.4 | −6.5 | −6.9 | −6.8 | −7.18 |
| 21 | Omeprazole | −6.6 | −6.6 | −6.6 | −6.8 | −6.8 | −6.8 | −6.40 |
| 22 | Oxytetracycline | −7.3 | −7.3 | −7.3 | −6.7 | −6.7 | −6.7 | −6.60 |
| 23 | PX-12 | −3.8 | −3.8 | −3.8 | −4.1 | −4.2 | −4.5 | −6.39 |
| 24 | Shikonin | −6.1 | −6.1 | −6.1 | −7.0 | −6.9 | −6.9 | −6.58 |
The experimental binding free energies were gained based on IC50 value,[12–18] approximating that the one equals to the inhibition constant ki. The unit is of kcal mol−1.
Fig. 2Correlation between docking results of ligands to monomeric and dimeric forms of SARS-CoV-2 Mpro. Computational results were obtained using Autodock Vina. The computed error was attained via 1000 rounds of the bootstrapping method.[44]
Fig. 3The superposition of the compound 7j in the binding mode with the monomeric and dimeric SARS-CoV-2 Mpro. In particular, the green and slate colors mentioned the monomeric and dimeric complexes, correspondingly.
Fig. 4Correlation and RMSE values between docking binding affinity of ligands to monomeric and dimeric forms of SARS-CoV-2 Mpro.
Computed values of rupture force and pulling work in comparison with experimental data of ligands to SARS-CoV-2 Mpro
| No. | Name |
|
|
|
| Δ |
|---|---|---|---|---|---|---|
| 1 | 7j | 575.3 ± 32.3 | 57.9 ± 3.9 | 583.6 ± 33.8 | 60.5 ± 4.2 | −8.69 |
| 2 | 11a | 761.0 ± 27.0 | 73.8 ± 3.3 | 860.2 ± 31.3 | 95.7 ± 3.9 | −9.96 |
| 3 | 11b | 735.4 ± 40.5 | 74.2 ± 3.9 | 814.0 ± 52.5 | 80.7 ± 4.9 | −10.13 |
| 4 | 11r | 724.8 ± 57.7 | 77.6 ± 7.1 | 636.6 ± 28.2 | 71.5 ± 2.9 | −9.23 |
| 5 | 13a | 526.9 ± 56.4 | 54.4 ± 7.3 | 769.6 ± 16.3 | 84.7 ± 3.2 | −7.70 |
| 6 | 13b | 977.6 ± 33.7 | 106.1 ± 4.6 | 739.1 ± 28.4 | 81.6 ± 3.0 | −8.45 |
| 7 | Calpain inhibitor I | 625.0 ± 26.3 | 57.9 ± 2.7 | 683.2 ± 34.1 | 63.4 ± 2.5 | −6.94 |
| 8 | Calpain inhibitor II | 592.5 ± 31.5 | 54.4 ± 3.5 | 497.4 ± 29.1 | 44.6 ± 4.3 | −8.23 |
| 9 | Calpain inhibitor XII | 491.6 ± 20.5 | 46.0 ± 2.3 | 693.6 ± 50.7 | 63.5 ± 4.8 | −8.69 |
| 10 | Calpeptin | 446.8 ± 16.9 | 33.4 ± 2.2 | 662.7 ± 32.5 | 62.5 ± 3.6 | −6.81 |
| 11 | Candesartan cilexetil | 547.2 ± 38.0 | 51.4 ± 5.3 | 510.7 ± 39.3 | 49.7 ± 3.4 | −7.60 |
| 12 | Carmofur | 485.5 ± 34.2 | 36.2 ± 2.7 | 436.9 ± 16.3 | 33.6 ± 1.8 | −7.86 |
| 13 | Chloroquine | 363.4 ± 32.1 | 28.5 ± 2.8 | 410.9 ± 12.5 | 36.0 ± 1.6 | −7.41 |
| 14 | Dipyridamole | 547.2 ± 38.0 | 51.4 ± 5.3 | 507.5 ± 18.7 | 51.0 ± 2.4 | −8.52 |
| 15 | Disulfiram | 364.7 ± 24.7 | 22.7 ± 1.9 | 526.2 ± 30.3 | 40.1 ± 1.9 | −6.89 |
| 16 | GC-373 | 616.9 ± 34.0 | 58.2 ± 4.4 | 557.3 ± 39.9 | 52.0 ± 5.2 | −8.76 |
| 17 | Hydroxychloroquine | 392.0 ± 27.2 | 30.2 ± 3.1 | 307.7 ± 24.9 | 22.4 ± 2.9 | −7.58 |
| 18 | MG-115 | 564.8 ± 26.4 | 56.6 ± 2.5 | 708.8 ± 31.1 | 70.6 ± 3.5 | −7.53 |
| 19 | MG-132 | 543.2 ± 22.2 | 49.8 ± 2.1 | 505.7 ± 41.1 | 47.5 ± 6.0 | −7.41 |
| 20 | Narlaprevir | 601.8 ± 31.9 | 64.8 ± 2.8 | 522.0 ± 38.3 | 54.7 ± 4.3 | −7.18 |
| 21 | Omeprazole | 478.6 ± 24.0 | 38.1 ± 2.2 | 413.3 ± 33.1 | 31.7 ± 3.2 | −6.40 |
| 22 | Oxytetracycline | 447.2 ± 21.6 | 37.0 ± 2.9 | 432.4 ± 49.6 | 37.7 ± 4.8 | −6.60 |
| 23 | PX-12 | 295.0 ± 17.4 | 13.7 ± 1.2 | 382.0 ± 25.5 | 27.2 ± 2.0 | −6.39 |
| 24 | Shikonin | 321.8 ± 29.7 | 19.7 ± 3.0 | 504.5 ± 22.8 | 39.1 ± 1.2 | −6.58 |
The experimental binding free energies were gained based on IC50 value,[12–18] approximating that the one equals to the inhibition constant ki. The unit of force and energy/work are in pN and kcal mol−1, respectively.
Fig. 5Relationship between rupture forces of the SARS-CoV-2 Mpro monomer and dimer. Rupture forces were obtained via FPL calculations. The computed error was attained via 1000 rounds of the bootstrapping method.[44]
Fig. 6Association between calculated pulling work of the monomeric and dimeric SARS-CoV-2 Mpro. The computed error was attained via 1000 rounds of the bootstrapping method.[44]
Computed values of docking, rupture force and pulling work in comparison with experimental data of ligands to SARS-CoV-2
| No. | Name | Δ | Δ |
|
|
|
| Δ | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Short | Medium | Long | Short | Medium | Long | |||||||
| 1 | Bazedoxifene | −7.4 | −7.5 | −7.4 | −7.4 | −7.4 | −7.5 | 460.3 ± 26.0 | 41.2 ± 3.1 | 471.1 ± 20.0 | 47.5 ± 3.6 | −7.48 |
| 2 | Cyclosporine | −5.8 | −5.7 | −5.7 | −5.4 | −5.4 | −5.4 | 638.8 ± 33.4 | 67.7 ± 5.4 | 426.5 ± 41.6 | 44.1 ± 4.7 | −7.17 |
| 3 | Digitoxin | −8.1 | −8.1 | −8.2 | −7.0 | −7.0 | −7.2 | 667.4 ± 17.7 | 70.9 ± 2.1 | 502.6 ± 65 | 55.3 ± 8.3 | −9.09 |
| 4 | Digoxin | −8.1 | −8.1 | −8.1 | −7.1 | −7.2 | −7.2 | 637.0 ± 30.3 | 75.0 ± 2.5 | 573.1 ± 42.3 | 59.4 ± 4.9 | −9.20 |
| 5 | Dihydrogambogic acid | −7.0 | −7.0 | −7.0 | −7.2 | −7.2 | −7.2 | 542.8 ± 37.7 | 59.6 ± 3.2 | 487.5 ± 29.9 | 44.0 ± 3.3 | −6.67 |
| 6 | Ebastine | −5.7 | −6.5 | −6.1 | −6.5 | −6.3 | −6.4 | 447.5 ± 40.1 | 40.2 ± 3.5 | 389.8 ± 25.0 | 32.8 ± 2.8 | −7.06 |
| 7 | Favipiravir | −4.5 | −4.8 | −4.8 | −5.0 | −5.0 | −5.0 | 364.9 ± 26.2 | 21.3 ± 2.9 | 336.1 ± 19.1 | 20.5 ± 2.5 | −4.52 |
| 8 | Fluspirilene | −6.9 | −7.2 | −7.3 | −8.0 | −7.7 | −7.6 | 490.1 ± 23.6 | 43.8 ± 2.0 | 544.6 ± 36.3 | 58.0 ± 3.2 | −7.53 |
| 9 | Isoosajin | −7.7 | −7.7 | −7.7 | −8.0 | −8.0 | −8.0 | 393.1 ± 32.8 | 28.9 ± 3.2 | 454.4 ± 19.7 | 40.4 ± 2.5 | −7.52 |
| 10 | Ivacaftor | −6.7 | −6.7 | −6.7 | −7.2 | −7.6 | −7.5 | 347.9 ± 34.8 | 22.3 ± 4.4 | 477.5 ± 22.1 | 41.0 ± 2.1 | −7.10 |
| 11 | Lusutrombopag | −6.2 | −6.1 | −6.8 | −6.4 | −6.5 | −6.3 | 540.6 ± 37.5 | 59.1 ± 3.7 | 396.8 ± 24.3 | 41.8 ± 2.2 | −7.42 |
| 12 | Mefloquine | −6.5 | −6.5 | −6.5 | −7.6 | −7.7 | −7.6 | 523.7 ± 23.5 | 41.5 ± 2.3 | 509.6 ± 43.3 | 46.3 ± 3.3 | −7.34 |
| 13 | Mequitazine | −6.6 | −6.6 | −6.6 | −6.3 | −6.3 | −6.3 | 392.5 ± 51.3 | 29.5 ± 4.0 | 384.9 ± 24.4 | 29.0 ± 2.2 | −7.03 |
| 14 | Osajin | −6.8 | −6.9 | −6.8 | −7.6 | −8.0 | −8.0 | 367.9 ± 20.4 | 30.8 ± 2.9 | 471.4 ± 23.9 | 39.8 ± 1.8 | −7.41 |
| 15 | Oxyclozanide | −6.4 | −6.4 | −6.4 | −6.7 | −6.7 | −6.7 | 463.7 ± 31.7 | 33.6 ± 3.2 | 468.1 ± 13.3 | 39.2 ± 3.5 | −7.44 |
| 16 | Penfluridol | −7.0 | −6.9 | −6.9 | −8.0 | −8.2 | −8.2 | 542.3 ± 33.1 | 53.3 ± 2.7 | 444.5 ± 25.0 | 48.0 ± 3.9 | −7.26 |
| 17 | Phenazopyridine | −6.0 | −6.0 | −6.0 | −6.0 | −6.0 | −6.0 | 391.7 ± 36.2 | 25.6 ± 2.8 | 384.8 ± 22.7 | 32.4 ± 1.4 | −6.23 |
| 18 | Proscillaridin | −7.7 | −7.7 | −7.7 | −6.8 | −7.3 | −7.3 | 485.6 ± 37.2 | 45.8 ± 3.3 | 512.8 ± 18.9 | 58.0 ± 1.6 | −7.79 |
| 19 | Tetrandrine | −6.6 | −6.6 | −6.6 | −6.8 | −6.8 | −6.8 | 485.6 ± 37.2 | 45.8 ± 3.3 | 401.5 ± 18.5 | 31.6 ± 1.8 | −7.56 |
The experimental binding free energies were gained based on IC50 value,[20,21] approximating that the one equals to the inhibition constant ki. The unit of force and energy/work are in pN and kcal mol−1, respectively.